Microba Life Sciences Limited
Microba Life Sciences Limited (MAP.AX) Stock Competitors & Peer Comparison
See (MAP.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MAP.AX | A$0.09 | -3.26% | 47.4M | -3.07 | -A$0.03 | N/A |
| SHL.AX | A$27.34 | -1.30% | 13.6B | 24.22 | A$1.14 | +3.88% |
| IDX.AX | A$2.68 | +0.37% | 993.8M | 133.50 | A$0.02 | +2.17% |
| HLS.AX | A$0.76 | -1.95% | 559.1M | -0.80 | -A$0.96 | +82.44% |
| ACL.AX | A$2.71 | -3.21% | 538M | 18.40 | A$0.15 | +4.53% |
| MVF.AX | A$0.80 | +0.63% | 311.7M | -80.00 | -A$0.01 | +6.38% |
| GSS.AX | A$0.34 | +2.41% | 75M | -3.30 | -A$0.10 | N/A |
| PEB.AX | A$0.09 | +0.00% | 69M | -2.83 | -A$0.03 | N/A |
| LDX.AX | A$0.08 | +10.96% | 54.6M | -7.30 | -A$0.01 | N/A |
| IIQ.AX | A$0.40 | +8.22% | 43M | -5.50 | -A$0.07 | N/A |
Stock Comparison
MAP.AX vs SHL.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, SHL.AX has a market cap of 13.6B. Regarding current trading prices, MAP.AX is priced at A$0.09, while SHL.AX trades at A$27.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas SHL.AX's P/E ratio is 24.22. In terms of profitability, MAP.AX's ROE is -0.48%, compared to SHL.AX's ROE of +0.07%. Regarding short-term risk, MAP.AX is more volatile compared to SHL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check SHL.AX's competition here
MAP.AX vs IDX.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, IDX.AX has a market cap of 993.8M. Regarding current trading prices, MAP.AX is priced at A$0.09, while IDX.AX trades at A$2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas IDX.AX's P/E ratio is 133.50. In terms of profitability, MAP.AX's ROE is -0.48%, compared to IDX.AX's ROE of +0.01%. Regarding short-term risk, MAP.AX is more volatile compared to IDX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check IDX.AX's competition here
MAP.AX vs HLS.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, HLS.AX has a market cap of 559.1M. Regarding current trading prices, MAP.AX is priced at A$0.09, while HLS.AX trades at A$0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas HLS.AX's P/E ratio is -0.80. In terms of profitability, MAP.AX's ROE is -0.48%, compared to HLS.AX's ROE of -0.02%. Regarding short-term risk, MAP.AX is more volatile compared to HLS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check HLS.AX's competition here
MAP.AX vs ACL.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, ACL.AX has a market cap of 538M. Regarding current trading prices, MAP.AX is priced at A$0.09, while ACL.AX trades at A$2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas ACL.AX's P/E ratio is 18.40. In terms of profitability, MAP.AX's ROE is -0.48%, compared to ACL.AX's ROE of +0.18%. Regarding short-term risk, MAP.AX is more volatile compared to ACL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check ACL.AX's competition here
MAP.AX vs MVF.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, MVF.AX has a market cap of 311.7M. Regarding current trading prices, MAP.AX is priced at A$0.09, while MVF.AX trades at A$0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas MVF.AX's P/E ratio is -80.00. In terms of profitability, MAP.AX's ROE is -0.48%, compared to MVF.AX's ROE of -0.01%. Regarding short-term risk, MAP.AX is more volatile compared to MVF.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check MVF.AX's competition here
MAP.AX vs GSS.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, GSS.AX has a market cap of 75M. Regarding current trading prices, MAP.AX is priced at A$0.09, while GSS.AX trades at A$0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas GSS.AX's P/E ratio is -3.30. In terms of profitability, MAP.AX's ROE is -0.48%, compared to GSS.AX's ROE of -0.39%. Regarding short-term risk, MAP.AX is more volatile compared to GSS.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check GSS.AX's competition here
MAP.AX vs PEB.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, PEB.AX has a market cap of 69M. Regarding current trading prices, MAP.AX is priced at A$0.09, while PEB.AX trades at A$0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas PEB.AX's P/E ratio is -2.83. In terms of profitability, MAP.AX's ROE is -0.48%, compared to PEB.AX's ROE of -0.86%. Regarding short-term risk, MAP.AX is more volatile compared to PEB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check PEB.AX's competition here
MAP.AX vs LDX.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, LDX.AX has a market cap of 54.6M. Regarding current trading prices, MAP.AX is priced at A$0.09, while LDX.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas LDX.AX's P/E ratio is -7.30. In terms of profitability, MAP.AX's ROE is -0.48%, compared to LDX.AX's ROE of -0.59%. Regarding short-term risk, MAP.AX is less volatile compared to LDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.Check LDX.AX's competition here
MAP.AX vs IIQ.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, IIQ.AX has a market cap of 43M. Regarding current trading prices, MAP.AX is priced at A$0.09, while IIQ.AX trades at A$0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas IIQ.AX's P/E ratio is -5.50. In terms of profitability, MAP.AX's ROE is -0.48%, compared to IIQ.AX's ROE of -0.36%. Regarding short-term risk, MAP.AX is more volatile compared to IIQ.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check IIQ.AX's competition here
MAP.AX vs CTE.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, CTE.AX has a market cap of 36.6M. Regarding current trading prices, MAP.AX is priced at A$0.09, while CTE.AX trades at A$0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas CTE.AX's P/E ratio is 18.75. In terms of profitability, MAP.AX's ROE is -0.48%, compared to CTE.AX's ROE of +1.33%. Regarding short-term risk, MAP.AX is more volatile compared to CTE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check CTE.AX's competition here
MAP.AX vs BDX.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, BDX.AX has a market cap of 21.2M. Regarding current trading prices, MAP.AX is priced at A$0.09, while BDX.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas BDX.AX's P/E ratio is -1.93. In terms of profitability, MAP.AX's ROE is -0.48%, compared to BDX.AX's ROE of -0.90%. Regarding short-term risk, MAP.AX is more volatile compared to BDX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check BDX.AX's competition here
MAP.AX vs RHY.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, RHY.AX has a market cap of 17.4M. Regarding current trading prices, MAP.AX is priced at A$0.09, while RHY.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas RHY.AX's P/E ratio is -6.00. In terms of profitability, MAP.AX's ROE is -0.48%, compared to RHY.AX's ROE of -0.76%. Regarding short-term risk, MAP.AX is more volatile compared to RHY.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check RHY.AX's competition here
MAP.AX vs GTG.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, GTG.AX has a market cap of 5.7M. Regarding current trading prices, MAP.AX is priced at A$0.09, while GTG.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas GTG.AX's P/E ratio is -3.90. In terms of profitability, MAP.AX's ROE is -0.48%, compared to GTG.AX's ROE of -3.62%. Regarding short-term risk, MAP.AX is more volatile compared to GTG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check GTG.AX's competition here
MAP.AX vs IBX.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, IBX.AX has a market cap of 3M. Regarding current trading prices, MAP.AX is priced at A$0.09, while IBX.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas IBX.AX's P/E ratio is -0.30. In terms of profitability, MAP.AX's ROE is -0.48%, compared to IBX.AX's ROE of +0.55%. Regarding short-term risk, MAP.AX is more volatile compared to IBX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check IBX.AX's competition here
MAP.AX vs WFL.AX Comparison August 2025
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 47.4M. In comparison, WFL.AX has a market cap of 1.5M. Regarding current trading prices, MAP.AX is priced at A$0.09, while WFL.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -3.07, whereas WFL.AX's P/E ratio is -0.10. In terms of profitability, MAP.AX's ROE is -0.48%, compared to WFL.AX's ROE of +11.65%. Regarding short-term risk, MAP.AX is more volatile compared to WFL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check WFL.AX's competition here